DrugPatentWatch Database Preview
XERAVA Drug Profile
Which patents cover Xerava, and what generic alternatives are available?
Xerava is a drug marketed by Tetraphase Pharms and is included in one NDA. There are two patents protecting this drug.
This drug has sixty-four patent family members in twenty-nine countries.
The generic ingredient in XERAVA is eravacycline dihydrochloride. One supplier is listed for this compound. Additional details are available on the eravacycline dihydrochloride profile page.
Summary for XERAVA
| International Patents: | 64 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for XERAVA |
| DailyMed Link: | XERAVA at DailyMed |
Generic Entry Opportunity Date for XERAVA
Generic Entry Date for XERAVA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for XERAVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XERAVA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2323972 | Start Trial |
| South Korea | 20160052813 | Start Trial |
| Japan | 2011530534 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for XERAVA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2323972 | CR 2019 00009 | Denmark | Start Trial | PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209 |
| 2323972 | 300971 | Netherlands | Start Trial | PRODUCT NAME: ERAVACYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/18/1312 20180924 |
| 2323972 | LUC00107 | Luxembourg | Start Trial | PRODUCT NAME: XERAVA - ERAVACYLINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
